Your browser doesn't support javascript.
loading
Efficacy of alectinib for ALK-positive NSCLC brain metastases / 中国肿瘤临床
Chinese Journal of Clinical Oncology ; (24): 661-665, 2021.
Article Dans Chinois | WPRIM | ID: wpr-861634
ABSTRACT

Objective:

To investigate the effect of alectinib in the treatment of brain metastases from anaplastic lymphoma kinase(ALK)positive non-small cell lung cancer (NSCLC).

Methods:

Thirty-four cases of ALK-positive NSCLC in Tianjin Medical University Cancer Institute and Hospital, between August 2016 to October 2019, were retrospectively analyzed. Thirteen cases received first-line single drug therapy (600 mg PO bid) of Alectinib. 7 cases (53.8%) were male, 6 cases were female (46.2%), the median age was 51 (35-72). The Kaplan-Meier method was used to examine progression-free survival (PFS).

Results:

The median progression-free survival (mPFS) of the alectinib group was 24.5 months, and the adverse drug reactions were mild.

Conclusions:

The use of alectinibas first-line treatment after the local treatment of measurable intracranial lesions significantly increased the PFS of patients with brain metastases from ALK-positive NSCLC.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Chinese Journal of Clinical Oncology Année: 2021 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Chinese Journal of Clinical Oncology Année: 2021 Type: Article